DrugPatentWatch Database Preview

Glaxo Grp England Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXO GRP ENGLAND, and what generic alternatives to GLAXO GRP ENGLAND drugs are available?

GLAXO GRP ENGLAND has one approved drug.

There are ten US patents protecting GLAXO GRP ENGLAND drugs.

There are one hundred and forty-five patent family members on GLAXO GRP ENGLAND drugs in thirty-nine countries and fourteen supplementary protection certificates in eleven countries.

Summary for Glaxo Grp England

International Patents:	145
US Patents:	10
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Glaxo Grp England

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014		RX	Yes	Yes	7,488,827		Y	Y
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014		RX	Yes	Yes	8,746,242		Y
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014		RX	Yes	Yes	8,183,257
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014		RX	Yes	Yes	9,333,310		Y

Expired US Patents for Glaxo Grp England

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014	5,873,360

Non-Orange Book US Patents for Glaxo Grp England

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,144,571	Muscarinic acetylcholine receptor antagonists
8,575,347	Muscarinic acetylcholine receptor antagonists
9,045,469	Muscarinic acetylcholine receptor antagonists
8,853,404	Muscarinic acetylcholine receptor antagonists

International Patents for Glaxo Grp England Drugs

Country	Document Number	Estimated Expiration
Slovenia	1740177
United Kingdom	0317374
Mexico	PA06009133
Norway	20064006

Supplementary Protection Certificates for Glaxo Grp England Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0140032 00132	Estonia		PRODUCT NAME: UMEKLIDIINBROMIID;REG NO/DATE: EU/1/14/922 30.04.2014
2014038	Lithuania		PRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428
00694	Netherlands		PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
C0075	France		PRODUCT NAME: BROMURE D'UMECLIDINIUM; REGISTRATION NO/DATE: EU/1/14/922 001-003 20140428

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Glaxo Grp England
• Glaxo Grp Ltd
• Glaxosmithkline
• Glaxosmithkline Con